Aethlon Medical Plans Conference Call for Financial Results Release
Aethlon Medical, Inc. (Nasdaq: AEMD), a prominent player in medical therapeutics, has announced its plans to share financial results for the fiscal third quarter, highlighting their commitment to transparency and communication with stakeholders. The results, covering the period that ended on December 31, 2025, are set to be disclosed on February 12, 2026, at 4:15 p.m. ET.
The management team will subsequently host a conference call to discuss these results along with recent corporate developments. This event is scheduled for the same day, starting at 4:30 p.m. ET, and will provide an interactive platform for stakeholders to engage through a question and answer session.
How to Participate in the Conference Call
For those interested in participating, registration is required. Attendees can easily register for the call by visiting the designated registration page. Registered participants will receive their unique dial-in details, ensuring a seamless joining experience.
In the event that some stakeholders cannot register online or lack internet access, Aethlon Medical offers a toll-free number for participants. The customer support team encourages all callers to specify they are joining the Aethlon Medical conference call for clarity.
Replay Information and Accessibility
For attendees who wish to replay the call, Aethlon Medical will provide access approximately one hour post-call. By March 12, 2026, interested parties can access the replay via the company's website or through dedicated phone lines for US, Canadian, and international callers. This flexibility ensures that all interested parties can stay informed about Aethlon's financial health and upcoming endeavors.
About Aethlon Medical and the Hemopurifier
Aethlon Medical is on the cutting edge of medical innovation, particularly with its unique device known as the Hemopurifier. This clinical stage immunotherapeutic device is designed to address severe health challenges posed by cancer and dangerous viral infections. During human studies, the Hemopurifier has exhibited its capability to eliminate life-threatening viruses, and in pre-clinical settings, it has shown promise in extracting harmful exosomes from body fluids using proprietary lectin-based technology.
The impact of the Hemopurifier is profound, particularly in oncology, where exosomes are implicated in immune suppression and cancer metastasis. This device has received special recognition from the U.S. Food and Drug Administration (FDA), being designated as a Breakthrough Device, which indicates its potential in treating advanced or metastatic cancers that are resistant to current therapies. Moreover, it has ongoing FDA Breakthrough Device designation and an open Investigational Device Exemption application involving treatments for critical viral infections.
Company Leadership and Contact Information
Leading Aethlon Medical is Jim Frakes, who serves as both Chief Executive Officer and Chief Financial Officer. Under his guidance, the company continues to strive for breakthroughs in medical technology, aiming to better the lives of patients worldwide.
Additionally, the firm values communication with investors and stakeholders. Susan Noonan from S.A. Noonan Communications facilitates investor relations, ensuring that inquiries regarding the company’s progress, innovations, and plans are addressed promptly.
Frequently Asked Questions
What financial results will Aethlon Medical share?
Aethlon Medical will disclose its fiscal third quarter financial results for the period ending December 31, 2025.
When will the conference call take place?
The conference call is scheduled for February 12, 2026, at 4:30 p.m. ET.
How can stakeholders participate in the call?
Interested parties can register online to receive dial-in information or call the designated number for participants without internet access.
Will the call be available for later listening?
Yes, a replay of the conference call will be available starting one hour after the call and accessible until March 12, 2026.
What is the focus of Aethlon Medical?
Aethlon Medical focuses on developing innovative therapies for treating cancer and life-threatening viral infections, primarily through its Hemopurifier device.
